Increasing knowledge of genes and their biological pathways associated with cancer development and progression has provided opportunities to develop targeted therapeutics for cancer treatment with higher specificity, more efficiency and safety. Here, we identify SOX6 as a tumor suppressor in esophageal squamous cell carcinoma (ESCC). Loss of SOX6 expression is significantly correlated with poor prognosis in ESCC patients. The tumor-suppressive mechanism of SOX6 is associated with its role in G1/S cell cycle arrest via the up-regulation of p53 and p21 WAF1/CIP1 , along with the down-regulation of cyclin D1/CDK4, cyclin A and β-catenin. These findings suggest that SOX6 could be used as a prognostic marker and a potential therapeutic target in ESCC.
Introduction
Esophageal squamous cell carcinoma (ESCC) is one of the most common fatal malignances of the digestive tract (1) . Despite advances in diagnosis and multimodality therapies, ESCC continues to carry a grim prognosis (2) . The major reason for this poor survival is the fact that ESCC frequently metastasizes to regional and distant lymph nodes, even at initial diagnosis. Recently, the treatment of cancer using molecular targets has brought promising results and attracted more and more attention. However, most of the molecular targets, which were commonly found in other epithelial neoplasias, have failed to demonstrate prognostic value for ESCC (3) . Hence, characterization of genes involved in the development and progression of ESCC may lead to the identification of new prognostic markers and therapeutic targets (4, 5) .
Systematic analysis of expression levels of thousands of genes by cDNA microarray is an effective approach to identify novel genes and pathways with importance in cancer development and progression, or as targets for new therapies. Recently, genome-wide expression profiles between pooled cDNA from 10 primary ESCCs and their corresponding nontumorous tissues were compared by cDNA microarray containing 47,000 genes. Using an arbitrary cutoff line at Signal Log Ratio ≥2.0 or ≤-2.0, 185 up-regulated genes and 225 down-regulated genes were detected in ESCC tumors as compared to normal controls (unpublished data). One frequently down-regulated gene in ESCC specimen, SOX6, was further characterized. SOX6, a member of the D subfamily of sex determining region y-related transcription factors, encodes a protein that binds to DNA through a high-mobility-group (HMG) domain and plays critical roles in cell fate determination, TG. GAPDH gene was used as a control.
Tissue microarray (TMA) and immunohistochemistry (IHC). TMAs containing 300
pairs of primary ESCC tissue samples and their corresponding nontumorous tissues were constructed as described previously (17) . Standard streptavidin-biotin-peroidase complex method was used for IHC staining (17) . Briefly, TMA section was deparaffinized, blocked with 10% normal rabbit serum for 10min, and incubated with anti-SOX6 polyclonal antibody (Novous, 1:75 dilution) overnight at 4°C. The TMA section was then incubated with biotinylated goat anti-rabbit immunoglobulin at a concentration of 1:75 at 37°C for 30min.
The status of nuclear expression of SOX6 was assessed by three independent investigators without prior knowledge of clinicopathologic data. Positive expression of SOX6 in normal and malignant ESCC tissues was primarily a nuclear pattern. Because the intensity of staining within each tumor tissue core was mostly homogeneous, the intensity of SOX6 staining was semi-quantitatively evaluated on the basis of criteria used by our previous publication (18) were estimated by univariate analyses. Multivariate survival analysis was carried out on all parameters that were found to be significant on univariate level using the Cox regression model. Differences were considered significant when P value was less than 0.05. (58%) of primary ESCCs (Fig. 1A) . Similarly, down-regulation of SOX6 was detected in 5 of 9 (EC109, HKESC1, KYSE30, 510 and 520) ESCC cell lines (Fig. 1B) .
Results

Down-regulation of SOX6 is frequently detected in
Down-regulation of SOX6 correlates with poor survival outcome in ESCC.
To investigate the clinical significance of down-regulation of SOX6 in esophageal carcinogenesis, SOX6 expression in protein level was also studied using ESCC tissue microarray containing 300 primary ESCC cases. The clinico-pathologic features of these cases were summarized in Table 1 . Positive staining of SOX6 was mainly observed at the nucleus (Fig. 1C) (Table 2) . Nevertheless, multivariate analysis showed that down-regulation of SOX6 and presence of lymph node metastasis were two independent prognostic predictors for ESCC patients enrolled in this study (P<0.001, Table 3 ). (Fig. 3B) . Cell growth assay also revealed that the cell growth rates in SOX6-30 cells were significantly inhibited by SOX6 (P<0.01) compared with Vec-30 cells (Fig. 3C) . A similar result was shown in SOX6-510 cells (Fig. 3D ).
SOX6 inhibits cell migration and invasion.
As the TMA result showed that down-regulation of SOX6 was closely associated with ESCC metastasis, the effects of SOX6 on cell migration and invasion were studied by wound-healing and cell invasion assays, respectively. Would-healing assay showed that the ectopic expression of SOX6 could dramatically inhibit cell migration ability in SOX6-transfectants compared with control cells ( in G0/G1 phases and in S-phase were significantly increased and decreased, respectively, compared with that in control cells, suggesting that SOX6 was able to inhibit DNA synthesis and G1/S phase transition (Fig. 5A and 5B). To further reveal the potential molecular mechanism of SOX6 in cell cycle arrest, the effects of SOX6 on several key cell cycle regulators, including p53, p21 WAF1/CIP1 , cyclin A, cyclin D1, CDK4 and β-catenin were investigated by Western blot analysis. Increased expression of p53 and p21 WAF1/CIP1 , down-regulation of cyclin D1/CDK4 complex, cyclin A and β-catenin were detected in SOX6-30 and SOX6-510 cells, compared with those in control cells (Fig. 5C ).
Discussion
The known functions of the SOX protein in development and disease are both diverse and complex (20) (21) (22) . In this study, we found that SOX6 was frequently down-regulated in ESCC cell lines and primary ESCC tumors. Tissue microarray study showed that the down-regulation of SOX6 was detected in 68% primary ESCCs, which was significantly associated with advanced stage, increased lymph node metastasis and poor survival of patients with ESCC. Multivariate analysis demonstrated that down-regulation of SOX6 could be used as an independent prognostic predictors for ESCC patients. In contrast, it has been reported that high SOX6 expression may be a potential diagnostic marker for some types of brain tumors (23, 24) . However, the biological role of high SOX6 expression in brain tumor is still unknown. The contradictory results indicated that SOX6 expression might thus be tissue specific. In this study, the mechanisms underlying silencing of SOX6 in ESCC 
